Compass Therapeutics, Inc. 8-K

What Happened
Compass Therapeutics, Inc. (CMPX) filed a Current Report on Form 8-K on July 1, 2026 (Item 7.01) to disclose an updated corporate presentation dated July 2026. The presentation was revised to reflect the company’s most recent corporate updates, specifically including data from the COMPANION-002 clinical study. The presentation is furnished as Exhibit 99.1 to the filing.

Key Details

• Filed: Form 8-K dated July 1, 2026 (Regulation FD disclosure, Item 7.01).
• Document: Corporate presentation dated July 2026 provided as Exhibit 99.1 (Item 9.01(d)).
• Content change: Presentation now includes data from the COMPANION-002 clinical study.
• Note: This 8-K discloses presentation updates; it does not report earnings, revenue, executive changes, or a merger.

Why It Matters
Public release of updated clinical data can be material for investors because it provides new information about the company’s development programs and may affect investor assessment of the pipeline. By filing under Regulation FD, Compass is publicly sharing information it views as important and ensuring fair disclosure. Investors should review the furnished presentation (Exhibit 99.1) for the specific COMPANION-002 data and any implications for timelines or development milestones.